ClinVar Miner

Submissions for variant NM_000251.2(MSH2):c.1321A>C (p.Thr441Pro) (rs587779086)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000524340 SCV000254382 uncertain significance Hereditary nonpolyposis colon cancer 2018-12-17 criteria provided, single submitter clinical testing This sequence change replaces threonine with proline at codon 441 of the MSH2 protein (p.Thr441Pro). The threonine residue is weakly conserved and there is a small physicochemical difference between threonine and proline. This variant is present in population databases (rs587779086, ExAC 0.005%). This variant has been reported in individuals affected with breast, ovarian and colon cancer (PMID: 25503501, 23047549, 18383312). ClinVar contains an entry for this variant (Variation ID: 90628). General algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD), and an algorithm developed specifically for the MSH2 gene (PMID: 22290698), suggest that this missense change is likely to be tolerated. However, these predictions have not been confirmed by published functional studies. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Color RCV000446874 SCV000537566 uncertain significance Hereditary cancer-predisposing syndrome 2018-10-01 criteria provided, single submitter clinical testing
GeneDx RCV000478413 SCV000565189 uncertain significance not provided 2018-10-15 criteria provided, single submitter clinical testing This variant is denoted MSH2 c.1321A>C at the cDNA level, p.Thr441Pro (T441P) at the protein level, and results in the change of a Threonine to a Proline (ACT>CCT). This variant has been observed in individuals with colorectal, pancreatic, ovarian, and breast cancer (Niessen 2006, Chao 2008, Pal 2012, Maxwell 2015). The International Society for Gastrointestinal Hereditary Tumors Incorporated (InSiGHT) classifies this variant as having uncertain clinical significance (Thompson 2014). MSH2 Thr441Pro was not observed at a significant allele frequency in large population cohorts (Lek 2016). This variant is located within the Lever domain and the region of interaction with MSH6 and MSH3 (Guerette 1998, L?tzen 2008, Kansikas 2011). In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function. Based on currently available evidence, it is unclear whether MSH2 Thr441Pro is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Ambry Genetics RCV000446874 SCV000662229 uncertain significance Hereditary cancer-predisposing syndrome 2017-06-19 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient or conflicting evidence

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.